5AM Ventures

5AM Ventures is a leading life science venture capital firm founded in 2002, currently investing $450M from 5AM Ventures VII and $300M from 5AM Opportunities II. The firm focuses on biopharmaceuticals, drug delivery technologies, and life science instruments, with a particular emphasis on early-stage private therapeutic companies at the Series A stage. 5AM evaluates innovative platform technologies, corporate spin-offs, and products with shorter development cycles across multiple therapeutic areas including oncology, neuroscience, rare diseases, and immunology. The firm is distinguished by its 'hands-on' approach to company building — going beyond passive board roles to assume short-term operating roles and proactively guide portfolio companies throughout their lifecycle. 5AM also operates the 4:59 Initiative, an internal incubator that discovers, incubates, and funds breakthrough science alongside academics and entrepreneurs to establish proof-of-concept data enabling Series A financings. The complementary 5AM Opportunities Strategy invests in small and mid-cap public and later-stage private biotech and life science companies, creating a dual-fund structure that follows successful companies into later stages.